CJC-1295 vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
CJC-1295Recovery & Repair
Larazotide Acetate- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- Local gut action; minimal systemic exposure
- Admin Route
- SubQ
- Oral
- Research
- —
- —
- Typical Dose
- 100 mcg
- 0.5-2 mg
- Frequency
- Once daily, before bed
- 3x daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —